What Is Mounjaro (Tirzepatide)? Risks and Side Effects

Mounjaro, whose active ingredient is tirzepatide, is a once-weekly weight loss and diabetes injection that temporarily suppresses appetite by sending satiety signals to the brain. Its potential harms and side effects include gastroparesis (stomach paralysis), acute pancreatitis, gallstones, the risk of thyroid tumors, severe gastrointestinal disorders, and rapid weight regain after discontinuation. During the weight loss process, these pharmacological agents provide only short-term and artificial cellular suppression while creating a lifelong need for continued use. Unlike safer methods such as gastric botox, which prolong satiety without altering the stomach’s natural anatomy, these externally administered chemical treatments may carry significant health risks due to systemic organ stress and aesthetic changes.

What Is Mounjaro (Tirzepatide)?

Our digestive system constantly communicates with the brain to regulate food intake. When we eat, our intestines release certain natural hormones that travel through the bloodstream to signal the brain that we are full. Mounjaro is a laboratory-developed molecule designed to mimic these natural satiety hormones. The medication simultaneously stimulates two different receptors known as Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1), continuously sending fullness signals to the brain. Administered as a once-weekly subcutaneous injection, it suppresses the appetite center in the brain and significantly reduces the desire to eat.

The effects of the medication are not limited to the brain. It also significantly slows the rate at which the stomach empties. Under normal circumstances, a meal passes from the stomach into the intestines within a few hours. During treatment, however, this process may take considerably longer. Because the stomach remains full for an extended period, individuals also experience prolonged physical satiety. Additionally, the drug stimulates the pancreas to increase insulin secretion while suppressing unnecessary glucose release from the liver into the bloodstream. Together, these effects contribute to blood sugar regulation and facilitate weight loss. However, it should not be forgotten that this is not a natural physiological process but rather a temporary suppression achieved through an externally administered chemical stimulus.

What Are the Gastrointestinal Harms and Side Effects of Using Mounjaro?

When the body’s natural rhythm is externally altered, the digestive system is often the first to respond. Although slowing stomach emptying may appear beneficial for weight loss, it can frequently lead to symptoms that significantly interfere with daily life. The prolonged retention of food in the stomach and reduced digestive motility may allow consumed food to remain in the stomach longer and undergo fermentation. Consequently, many patients experience persistent gastrointestinal discomfort throughout the day. If adequate fluid intake is not maintained, digestive complications may also result in dehydration and place additional strain on kidney function.

The adjustment period can be particularly challenging during dose escalation. Excessive slowing of gastric motility may contribute to the development of gastroparesis, a condition commonly referred to as stomach paralysis. In this condition, food may remain in the stomach for prolonged periods and potentially form blockages.

The most common digestive system complaints associated with treatment include:

• Severe nausea
• Persistent diarrhea
• Constipation
• Vomiting
• Indigestion
• Stomach cramps
• Abdominal bloating
• Heartburn and acid reflux

What Risks Does Mounjaro (Tirzepatide) Pose to the Pancreas and Gallbladder?

One of Mounjaro’s mechanisms of action is stimulating the pancreas to produce more insulin. The pancreas is an extremely delicate and essential organ responsible for maintaining blood sugar balance. Constant artificial stimulation may place excessive stress on the pancreas. As a result of prolonged overstimulation, inflammation of the pancreas may occur. Known medically as acute pancreatitis, this serious condition is characterized by severe abdominal pain radiating to the back, fever, and vomiting, often requiring hospitalization.

The gallbladder may also be adversely affected during treatment. The gallbladder stores bile produced by the liver and releases it into the intestines to aid fat digestion after meals. Rapid weight loss combined with a significant reduction in dietary fat intake may cause the gallbladder to become less active. Bile that is not regularly expelled may become concentrated, forming sludge and eventually gallstones. If these stones obstruct the bile ducts, they may cause severe pain and frequently require surgical removal of the gallbladder.

Organs that may be placed at risk due to rapid weight loss and medication-related effects include:

• Pancreas
• Gallbladder
• Bile ducts
• Liver
• Kidneys

Does Mounjaro Use Carry Serious Risks Such as Thyroid Cancer?

Laboratory testing performed during drug development provides valuable information regarding long-term safety. Animal studies conducted with tirzepatide have demonstrated stimulation of certain thyroid cells associated with the development of medullary thyroid carcinoma, a specific and aggressive type of thyroid cancer. Although long-term human data remain incomplete, regulatory authorities have considered these findings sufficiently important to include a boxed warning—the strongest safety warning available—in the prescribing information.

The thyroid gland, located at the front of the neck, regulates many vital functions, including metabolic rate and energy balance. Any abnormal cellular changes within this gland require careful evaluation. If symptoms such as a neck mass, persistent hoarseness, difficulty swallowing, or shortness of breath occur, the medication should be discontinued immediately and appropriate medical evaluation performed. Family history also plays an important role in determining individual risk.

The following groups are generally considered to be at particularly high risk when using this medication:

• Individuals with a family history of medullary thyroid carcinoma
• Individuals with Multiple Endocrine Neoplasia (MEN) syndrome
• Individuals with suspected active thyroid nodules
• Pregnant women
• Breastfeeding women

What Is “Mounjaro Face” and What Are Its Aesthetic Consequences?

The speed of weight loss directly influences how well the body adapts to physical changes. During gradual weight loss achieved through healthy nutrition and exercise, the skin has time to adjust as underlying fat tissue decreases, helping maintain its elasticity. However, when large amounts of fat are lost rapidly over a few months with medications such as tirzepatide, the tissues beneath the skin may not adapt quickly enough. As the facial fat pads responsible for maintaining youthful facial contours disappear rapidly, the collagen and elastin structure of the skin may succumb to gravity.

This aesthetic appearance has become popularly known as “Mounjaro face.” Rather than simply enjoying successful weight loss, many individuals find themselves looking significantly older, more fatigued, and less healthy than before. Consequently, some seek costly cosmetic procedures to tighten sagging skin or restore lost facial volume. In addition, the physiological stress associated with rapid weight loss frequently contributes to significant hair loss.

Potential effects on the skin and hair include:

• Pronounced hollowing of the cheeks
• Under-eye bags
• Neck skin sagging
• Loss of skin elasticity
• Significant hair loss
• Brittle nails

Is Weight Regained After Stopping Mounjaro, and Why Does It Return So Quickly?

One of the major limitations of these medications becomes apparent after treatment is discontinued. The human body has evolved to preserve survival and maintains a biological “set point” designed to defend its existing body weight. When substantial weight is lost rapidly through medication, the brain may interpret this change not as healthy weight reduction but as a state of starvation. Once the artificial satiety created by the medication disappears, the body activates powerful compensatory mechanisms to restore its previous weight.

Following discontinuation, production of the hunger hormone ghrelin by the stomach increases significantly. Many individuals experience even stronger hunger and food cravings than before treatment. Simultaneously, basal metabolic rate decreases as the body attempts to conserve energy. Together, these changes make calorie expenditure more difficult and promote rapid fat regain. Clinical studies have shown that many individuals regain a substantial proportion of their lost weight within the first year after stopping treatment.

Changes commonly observed during weight regain include:

• More intense hunger episodes than before treatment
• Strong cravings for sweets and carbohydrates
• Recurrence of blood sugar instability
• Elevated blood pressure
• Rapid fat accumulation around the waist
• Worsening cholesterol levels

What Are the Lifetime Financial and Psychological Challenges of Mounjaro Treatment?

The temporary nature of pharmacological obesity treatments often requires patients to continue therapy indefinitely. Even after achieving weight loss, maintaining results frequently depends on administering weekly injections, raising important questions regarding long-term sustainability. Depending on a chemical intervention for satiety may also reduce confidence in the body’s own natural appetite regulation.

One of the most significant burdens is financial. Manufacturing costs are high, and health insurance frequently does not cover weight loss medications. When the monthly cost of ongoing treatment is projected over many years, the financial burden may become substantial. Purchasing the medication every month indefinitely and worrying about potential weight regain if it becomes unavailable may create considerable psychological stress. Relying on a weekly injection for long-term body weight management may not provide the sense of independence many patients seek.

Challenges associated with prolonged treatment include:

• High lifetime financial burden
• Fear of medication shortages
• Fatigue associated with continuous injections
• Stress about missing scheduled doses
• Reduced enjoyment of daily life

Why Is Gastric Botox Different from Mounjaro Treatment as a Weight Management Option?

It is important to understand the distinction between systemic medications used in obesity treatment and local endoscopic procedures such as gastric botox. Gastric botox is a non-surgical endoscopic procedure that helps regulate stomach muscle activity and appetite, promoting a natural feeling of fullness without surgical incisions or organ removal. While medications circulate throughout the body and produce systemic effects by sending artificial satiety signals to the brain, gastric botox works locally on the stomach muscles, delaying gastric emptying and helping regulate appetite-related hormone release within the stomach.

Through this minimally invasive procedure, individuals may remain satisfied with much smaller portions without experiencing constant hunger. One of its primary advantages is that it does not require lifelong dependence on potent medications and preserves the anatomical integrity of the digestive organs. As stomach emptying slows after treatment, calorie intake naturally decreases, making healthy eating habits easier to establish while avoiding widespread systemic stress or organ fatigue.

Potential advantages of gastric botox include:

• No surgical incisions, sutures, or organ removal
• Local effects without systemic side effects
• Prolonged satiety by slowing stomach emptying
• Easier portion control
• Short procedure time (15–20 minutes) with same-day return to normal activities
• Elimination of lifelong medication dependence and associated financial burden

In Which Situations Can Mounjaro and Gastric Botox Be Used Together?

Every treatment method has its own place in obesity management. In selected situations, medical therapies and endoscopic procedures such as gastric botox may complement one another when applied using an appropriate strategy. Patients undergoing gastric botox often achieve portion control and develop healthier eating habits that help them reach their target weight. However, in cases of treatment-resistant obesity or severe eating disorders, gastric botox alone may not produce sufficient satiety.

In these specific situations, short-term treatment with low-dose medications such as Mounjaro may be considered under specialist supervision to support the satiety achieved with gastric botox. While gastric botox physically delays stomach emptying and promotes fullness, temporary medication may provide additional appetite suppression through central nervous system effects, helping overcome treatment-resistant obesity. In this way, patients may benefit from the complementary effects of both approaches without requiring lifelong exposure to high-dose pharmacological therapy.

Situations in which medication may occasionally support gastric botox treatment include:

• Accelerating weight loss in individuals with severe treatment-resistant obesity
• Overcoming weight loss plateaus
• Providing short-term support for patients struggling to adapt to dietary recommendations after gastric botox
• Managing selected cases in which appetite crises are triggered by emotional eating disorders

Dr. Ahmet Bekin

Op. Dr. Ahmet Bekin was born in Istanbul in 1983. He graduated from the Faculty of Medicine at Kocaeli University in 2006 and completed his specialty training in the Department of General Surgery at Istanbul University Çapa Faculty of Medicine in 2011. After his specialization, he worked in the fields of hernia surgery, reflux surgery, obesity surgery, advanced laparoscopic surgery, and robotic surgery. In addition, he received training in endocrine surgery, oncological surgery, and minimally invasive surgery. He is currently accepting patients from Turkey as well as from countries such as Germany and France at his private clinic located in Istanbul.